Naltrexone May Mitigate Stimulant-Induced Euphoria Associated With ADHD Treatment
Euphoria associated with the stimulant methylphenidate may be mitigated by co-administration of naltrexone in patients with attention-deficit/hyperactivity disorder.
Euphoria associated with the stimulant methylphenidate may be mitigated by co-administration of naltrexone in patients with attention-deficit/hyperactivity disorder.
Pharmacologic-only approaches to the management of chronic pain seldom provide complete/adequate pain relief and experts advocate for an integrative approach to the management of chronic pain.
New evidence suggests that stopping antibiotics sooner is a safe and effective way to reduce antibiotic overuse.
Boehringer Ingelheim has initiated a clinical study to investigate the interchangeability between an adalimumab biosimilar candidate and Humira.
These findings highlight an urgent need to produce more evidence on the risks and benefits of off-label antidepressant use.
There is good evidence for cognitive behavioral therapy and motivational approaches to dependence.
Much of the third world is suffering in pain without access to opioids. This imbalance has been called the opioid gap. How can we get opioids to patients who need them?
A recent study published in The Journal of Pain evaluated the effectiveness of a brief self-assessment tool called the Opioid Compliance Checklist in identifying adherence, or misuse, among patients prescribed opioids.
The drug assists the kidney excrete uric acid by impeding the function of transporter proteins involved in uric acid reabsorption in the kidney.
PAMORA strategy appears to safe with superior effectiveness.